Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer

BMC Cancer

Table 3 Univariate and multivariate analyses for overall survival

		Univariate		Multivariate
		Median
Variable	No.	survival	p-Value	HR (95% CI)	p-Value
BWL^a
< 10%	28	N.R.
≥ 10%	26	46	0.163		N.S.
Postoperative diarrhea
No	34	40
Yes	20	21	0.379		N.S.
Extended dissection of nerve plexus around SMA^b
No	39	67
Yes	15	22	0.011	3.289 (1.269–8.547)	0.014
Residual tumor
R0	47	53
R1	7	28	0.095	4.236 (1.336–13.42)	0.014
Lymph node metastasis
Negative	20	67
Positive	34	40	0.051		N.S.
AJCC Stage
Stage IA, IB		7	N.R.
Stage IIA or higher	47	28	0.026		N.S.
RDI in adjuvant chemotherapy
≥ 80%	11	N.R.
< 80%	43	46	0.045	4.437 (1.437–13.70)	0.010

^aBWL (body weight loss): % body weight loss = (preoperative body weight – body weight at the time of discharge) × 100 / preoperative body weight
^bExtended dissection of nerve plexus around SMA was defined as more than a half
RDI Relative dose intensity, N.R. not reached
Boldface indicates the statistical significance

ISSN: 1471-2407